Affiliations 

  • 1 Chemistry Section, School of Distance Education, Universiti Sains Malaysia, 11800, Minden, Penang, Malaysia
  • 2 Institute of Medical Science Technology, Universiti Kuala Lumpur, 43000, Kajang, Selangor, Malaysia. wytong@unikl.edu.my
  • 3 Bioprocess Technology, School of Industrial Technology, Universiti Sains Malaysia, 11800, Minden, Penang, Malaysia
  • 4 Advanced Medical and Dental Institute, Universiti Sains Malaysia, Bertam, 13200, Kepala Batas, Penang, Malaysia
  • 5 Malaysian Institute of Chemical and Bioengineering Technology, Universiti Kuala Lumpur, 78000, Alor Gajah, Melaka, Malaysia
  • 6 Chemistry Section, School of Distance Education, Universiti Sains Malaysia, 11800, Minden, Penang, Malaysia. tanwn@usm.my
Curr Microbiol, 2024 Mar 10;81(4):108.
PMID: 38461425 DOI: 10.1007/s00284-024-03627-7

Abstract

Methicillin-resistant Staphylococcus aureus (MRSA) infections have become one of the most threatening multidrug-resistant pathogens. Thus, an ongoing search for anti-MRSA compounds remains an urgent need to effectively treating MRSA infections. Phomopsidione, a novel antibiotic isolated from Diaporthe fraxini, has previously demonstrated potent anti-candidal activity. The present study aimed to investigate the effects of phomopsidione on the viability, virulence, and metabolites profile of MRSA. MRSA was sensitive to phomopsidione in a concentration-dependent manner. Phomopsidione exhibited minimum inhibitory concentration and minimum bactericidal concentration of 62.5 and 500.00 µg/mL against MRSA on broth microdilution assay. The compound showed significant reduction in virulence factors production including extracellular polymeric substances quantification, catalase, and lipase. An untargeted metabolomics analysis using liquid chromatography-high resolution mass spectrometry revealed a significant difference in the metabolites profile of MRSA with 13 putatively identified discriminant metabolites. The present study suggested the potential of phomopsidione as a promising anti-MRSA agent.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.